|
US5662896A
(en)
|
1988-03-21 |
1997-09-02 |
Chiron Viagene, Inc. |
Compositions and methods for cancer immunotherapy
|
|
US5591439A
(en)
*
|
1989-03-24 |
1997-01-07 |
The Wistar Institute Of Anatomy And Biology |
Recombinant cytomegalovirus vaccine
|
|
US5670488A
(en)
*
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
|
US5747469A
(en)
*
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
|
US6410010B1
(en)
*
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
CA2108144A1
(en)
*
|
1991-03-06 |
1992-09-07 |
Jack A. Roth |
Methods and compositions for the selective inhibition of gene expression
|
|
US6743623B2
(en)
|
1991-09-27 |
2004-06-01 |
Centre National De La Recherche Scientifique |
Viral recombinant vectors for expression in muscle cells
|
|
US6099831A
(en)
*
|
1992-09-25 |
2000-08-08 |
Centre National De La Recherche Scientifique |
Viral recombinant vectors for expression in muscle cells
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
FR2717496B1
(fr)
*
|
1994-03-18 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
EP0673431A1
(de)
*
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
|
|
US5846945A
(en)
*
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
FR2704234B1
(fr)
*
|
1993-04-22 |
1995-07-21 |
Centre Nat Rech Scient |
Virus recombinants, preparation et utilisation en therapie genique.
|
|
FR2705361B1
(fr)
*
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
AU727970B2
(en)
*
|
1993-05-28 |
2001-01-04 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
|
AU710962B2
(en)
*
|
1993-05-28 |
1999-09-30 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
|
US6133028A
(en)
*
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
US6080569A
(en)
*
|
1993-06-24 |
2000-06-27 |
Merck & Co., Inc. |
Adenovirus vectors generated from helper viruses and helper-dependent vectors
|
|
US6120764A
(en)
*
|
1993-06-24 |
2000-09-19 |
Advec, Inc. |
Adenoviruses for control of gene expression
|
|
US7045347B2
(en)
|
1993-06-24 |
2006-05-16 |
Advec, Inc. |
Helper dependent adenovirus vectors based on integrase family site-specific recombinases
|
|
US5919676A
(en)
*
|
1993-06-24 |
1999-07-06 |
Advec, Inc. |
Adenoviral vector system comprising Cre-loxP recombination
|
|
US20020136708A1
(en)
|
1993-06-24 |
2002-09-26 |
Graham Frank L. |
System for production of helper dependent adenovirus vectors based on use of endonucleases
|
|
US6140087A
(en)
*
|
1993-06-24 |
2000-10-31 |
Advec, Inc. |
Adenovirus vectors for gene therapy
|
|
EP0705344B8
(de)
*
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vektoren für gentherapie
|
|
US6730507B1
(en)
|
1993-06-24 |
2004-05-04 |
Merck & Co., Inc. |
Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
|
|
FR2710536B1
(fr)
*
|
1993-09-29 |
1995-12-22 |
Transgene Sa |
Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
|
|
DE69435223D1
(de)
*
|
1993-10-25 |
2009-09-03 |
Canji Inc |
Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
|
|
TW442569B
(en)
*
|
1993-10-25 |
2001-06-23 |
Canji Inc |
Recombinant adenoviral vector
|
|
FR2712602B1
(fr)
*
|
1993-11-18 |
1996-02-09 |
Centre Nat Rech Scient |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
FR2712603B1
(fr)
*
|
1993-11-18 |
1996-02-09 |
Centre Nat Rech Scient |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
FR2717497B1
(fr)
*
|
1994-03-18 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
FR2717495B1
(fr)
*
|
1994-03-18 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
IL113052A0
(en)
*
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
|
FR2726575B1
(fr)
*
|
1994-11-09 |
1996-12-20 |
Rhone Poulenc Rorer Sa |
Virus recombinants, preparation et utilisation en therapie genique
|
|
FR2717823B1
(fr)
*
|
1994-03-23 |
1996-04-26 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
FR2717824B1
(fr)
|
1994-03-25 |
1996-04-26 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
FR2718150B1
(fr)
*
|
1994-03-29 |
1996-04-26 |
Rhone Poulenc Rorer Sa |
Virus recombinants, préparation et utilisation en thérapie génique.
|
|
US7252989B1
(en)
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
|
US6379943B1
(en)
|
1999-03-05 |
2002-04-30 |
Merck & Co., Inc. |
High-efficiency Cre/loxp based system for construction of adenovirus vectors
|
|
AU711269B2
(en)
|
1994-08-16 |
1999-10-07 |
Crucell Holland B.V. |
Recombinant vectors derived from adenovirus for use in gene therapy
|
|
JP3822261B2
(ja)
*
|
1994-09-09 |
2006-09-13 |
財団法人癌研究会 |
癌の遺伝子治療剤
|
|
FR2725213B1
(fr)
*
|
1994-10-04 |
1996-11-08 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation en therapie genique
|
|
FR2725726B1
(fr)
*
|
1994-10-17 |
1997-01-03 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en therapie genique
|
|
CA2203809C
(en)
|
1994-10-28 |
2008-06-03 |
James M. Wilson |
Recombinant adenovirus and methods of use thereof
|
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
|
US5637456A
(en)
*
|
1995-02-17 |
1997-06-10 |
The University Of Texas, Board Of Regents |
Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
|
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
|
US6019978A
(en)
*
|
1995-06-05 |
2000-02-01 |
The Wistar Institute Of Anatomy And Biology |
Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
|
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
|
US5698202A
(en)
*
|
1995-06-05 |
1997-12-16 |
The Wistar Institute Of Anatomy & Biology |
Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
|
|
US6974694B2
(en)
|
1995-06-07 |
2005-12-13 |
Advec, Inc. |
Adenoviruses for control of gene expression
|
|
DE19643082C2
(de)
*
|
1995-10-18 |
2003-10-30 |
Volkswagen Ag |
Verfahren zum Innen- und Außenbeschichten einer Karosserie mit Hohlräumen
|
|
CN101028523A
(zh)
*
|
1995-11-30 |
2007-09-05 |
德克萨斯州立大学董事会 |
诊断和治疗肿瘤的方法及组合物
|
|
US6448389B1
(en)
|
1996-04-23 |
2002-09-10 |
The Wistar Institute Of Anatomy And Biology |
Human cytomegalovirus DNA constructs and uses therefor
|
|
US5958892A
(en)
|
1996-07-30 |
1999-09-28 |
Board Of Regents, The University Of Texas System |
2-methoxyestradiol-induced apoptosis in cancer cells
|
|
EP0834323A1
(de)
*
|
1996-09-30 |
1998-04-08 |
Introgene B.V. |
Cytokin-Gentherapie für die Behandlung von malignen Tumoren
|
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
|
US6884430B1
(en)
*
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
|
CA2294793A1
(fr)
|
1997-06-30 |
1999-01-14 |
Rhone-Poulenc Rorer S.A. |
Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
|
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
|
ATE446368T1
(de)
|
1998-01-14 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
|
MX343752B
(es)
|
1998-05-01 |
2016-11-22 |
Novartis Vaccines & Diagnostics Inc |
Antigenos de neisseria meningitidis y composiciones que los contienen.
|
|
US7691370B2
(en)
|
1998-10-15 |
2010-04-06 |
Canji, Inc. |
Selectivity replicating viral vector
|
|
ES2639020T3
(es)
|
1998-11-27 |
2017-10-25 |
Ucb Pharma S.A. |
Composiciones y métodos para incrementar la mineralización de la substancia ósea
|
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
NZ571167A
(en)
|
1999-04-30 |
2010-05-28 |
Novartis Vaccines & Diagnostic |
Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
|
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
|
FR2799472B1
(fr)
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
|
PT2275551E
(pt)
|
1999-10-29 |
2015-06-29 |
Novartis Vaccines & Diagnostic |
Péptidos antigénicos de neisseria
|
|
PT1232264E
(pt)
|
1999-11-18 |
2009-11-26 |
Novartis Vaccines & Diagnostic |
Gene fgf-21 humano e produtos da expressão do gene
|
|
ES2588917T3
(es)
|
2000-01-17 |
2016-11-07 |
Glaxosmithkline Biologicals Sa |
Vacuna de VME suplementada contra meningococo
|
|
EP1854476A3
(de)
|
2000-02-09 |
2008-05-07 |
Bas Medical, Inc. |
Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
|
|
WO2001066595A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
|
DE60134275D1
(de)
|
2000-06-15 |
2008-07-10 |
Novartis Vaccines & Diagnostic |
Polynukleotide zur bestimmung von kolonkrebs
|
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
|
WO2002046477A2
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
|
FR2829136B1
(fr)
|
2001-08-29 |
2006-11-17 |
Aventis Pharma Sa |
Derives lipidiques d'aminoglycosides
|
|
US20030086903A1
(en)
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
|
ATE466020T1
(de)
|
2001-11-09 |
2010-05-15 |
Univ Georgetown |
Neue isoform des gefässendothelzell wachstumshemmers (vegi)
|
|
ES2386386T3
(es)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunización contra Chlamydia trachomatis
|
|
EP1472375B1
(de)
|
2002-01-08 |
2009-04-01 |
Novartis Vaccines and Diagnostics, Inc. |
In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
|
|
EP1479985B1
(de)
|
2002-01-17 |
2017-06-14 |
Alfa Laval Corporate AB |
Getauchter Verdampfer umfassend einen Plattenwärmetauscher und ein zylindrisches Gehäuse in dem der Plattenwärmetauscher angeordnet ist
|
|
CA2479118A1
(en)
|
2002-03-15 |
2003-09-25 |
Wyeth Holdings Corporation |
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
|
WO2003080808A2
(en)
|
2002-03-21 |
2003-10-02 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
|
AU2003203527A1
(en)
*
|
2002-04-12 |
2003-10-30 |
Sumitomo Electric Industries, Ltd. |
Control of the ratio of lap to lip
|
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
|
WO2004032870A2
(en)
|
2002-10-08 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
|
|
US7255860B2
(en)
|
2002-10-08 |
2007-08-14 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
|
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
|
DK1575517T3
(da)
|
2002-12-24 |
2012-05-14 |
Rinat Neuroscience Corp |
Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
|
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
|
JP2007524362A
(ja)
|
2003-02-14 |
2007-08-30 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における治療gpcr標的
|
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
|
KR20050111598A
(ko)
|
2003-02-19 |
2005-11-25 |
리나트 뉴로사이언스 코퍼레이션 |
신경 성장 인자 길항제 및 nsaid를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
|
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
|
EP2353389B1
(de)
|
2003-04-21 |
2015-11-04 |
Epeius Biotechnologies Corporation |
Zusammensetzungen zur Behandlung von Erkrankungen
|
|
US20070178066A1
(en)
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
JP4503617B2
(ja)
|
2003-12-23 |
2010-07-14 |
ライナット ニューロサイエンス コーポレイション |
アゴニスト抗trkC抗体および該抗体を用いる方法
|
|
KR101222281B1
(ko)
|
2004-03-29 |
2013-01-28 |
가르파마 컴퍼니 리미티드 |
신규 갈렉틴 9 개변체 단백질 및 그 용도
|
|
KR101637908B1
(ko)
|
2004-04-07 |
2016-07-11 |
리나트 뉴로사이언스 코프. |
신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
|
|
TR201808440T4
(tr)
|
2004-07-09 |
2018-07-23 |
Henry M Jackson Found Advancement Military Medicine Inc |
Hendra ve nipah virüsü G glikoproteininin çözünebilen formları.
|
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
|
AU2005290250A1
(en)
|
2004-07-30 |
2006-04-06 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
尿路病原性菌株由来の抗原
|
|
CA2604844A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics, Inc. |
Cancer-related genes
|
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
|
RU2486204C2
(ru)
|
2005-07-22 |
2013-06-27 |
Уай'З Терапьютикс Ко., Лтд. |
Антитела против сd26 и способы их применения
|
|
SI3045182T1
(en)
|
2005-11-14 |
2018-08-31 |
Teva Pharmaceuticals International Gmbh |
An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
|
|
AU2007210862A1
(en)
*
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corp. |
Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
|
|
JP2009525319A
(ja)
*
|
2006-02-02 |
2009-07-09 |
ライナット ニューロサイエンス コーポレイション |
trkBアンタゴニストを投与することにより肥満を治療する方法
|
|
BRPI0712850A8
(pt)
|
2006-06-07 |
2018-05-02 |
Bioalliance Cv |
anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
WO2008013918A2
(en)
*
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
|
EP2586790A3
(de)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogene von uropathogenen Escherichia coli
|
|
EP2069500B1
(de)
*
|
2006-10-04 |
2014-09-24 |
Centre National De La Recherche Scientifique (Cnrs) |
Zusammensetzungen mit einer sirna und lipidischen 4,5-disubstituierten 2-desoxystreptaminring-aminoglykosid-derivaten und verwendungen davon
|
|
US20100029189A1
(en)
*
|
2007-03-27 |
2010-02-04 |
Wood Jeffrey H |
Methods for stiffening thin wall direct manufactured structures
|
|
AP2009005028A0
(en)
|
2007-04-10 |
2009-12-31 |
Univ Tulane |
Soluble and membrane-anchored forms of lassa virussubunit proteins
|
|
KR100896483B1
(ko)
|
2007-07-13 |
2009-05-08 |
연세대학교 산학협력단 |
Il-12 및 4-1bbl을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
JP5737944B2
(ja)
|
2007-12-17 |
2015-06-17 |
ファイザー・リミテッドPfizer Limited |
間質性膀胱炎の治療
|
|
CN105732813A
(zh)
|
2007-12-18 |
2016-07-06 |
生物联合公司 |
识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
|
|
AU2009234389B2
(en)
|
2008-04-10 |
2014-08-21 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR mutations in cancer
|
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
|
EP2331071A1
(de)
|
2008-09-05 |
2011-06-15 |
Institut National De La Sante Et De La Recherche Medicale |
Neue multimodulare anordnung zur intrazellulären abgabe
|
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
|
WO2010100632A2
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
|
EP2419129A2
(de)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Zusammensetzungen zur immunisierung gegen staphylococcus aerus
|
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
|
CA2768343A1
(en)
|
2009-07-16 |
2011-01-20 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
AR080291A1
(es)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas anti receptor de il-7 y procedimientos
|
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
NZ602220A
(en)
|
2010-03-11 |
2014-10-31 |
Rinat Neuroscience Corp |
Antibodies with ph dependent antigen binding
|
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
|
WO2012150478A1
(en)
*
|
2010-04-28 |
2012-11-08 |
Institut Gustave Roussy |
Adenovirus vaccine vectors
|
|
JP5988961B2
(ja)
|
2010-04-28 |
2016-09-07 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
心筋細胞を発生させるための方法
|
|
CA2798703A1
(en)
|
2010-05-10 |
2011-11-17 |
The Regents Of The University Of California |
Endoribonuclease compositions and methods of use thereof
|
|
US20130150256A1
(en)
|
2010-06-11 |
2013-06-13 |
Jane Synnergren |
Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
|
|
JP2013533286A
(ja)
|
2010-07-30 |
2013-08-22 |
セントルイス ユニバーシティ |
疼痛を治療する方法
|
|
EP2698635A3
(de)
|
2010-12-01 |
2014-05-28 |
The University Of North Carolina At Chapel Hill |
Verfahren und Zusammensetzungen zum Targeting auf Stellen neovaskulären Wachstums
|
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
CA2859364C
(en)
|
2011-12-16 |
2019-05-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Opsin polypeptides and methods of use thereof
|
|
RU2014123030A
(ru)
|
2011-12-22 |
2016-02-20 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
|
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
CN104582717B
(zh)
|
2012-07-19 |
2018-03-13 |
雷德伍德生物科技股份有限公司 |
对cd22有特异性的抗体及其使用方法
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
EP2885010B1
(de)
|
2012-08-16 |
2020-01-01 |
Ipierian, Inc. |
Verfahren zur behandlung einer tauopathie
|
|
WO2014066744A2
(en)
|
2012-10-25 |
2014-05-01 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
|
ES2912396T3
(es)
|
2012-11-02 |
2022-05-25 |
Bioverativ Usa Inc |
Anticuerpos anti-C1s del complemento y uso de los mismos
|
|
RU2015115956A
(ru)
|
2012-11-09 |
2017-01-10 |
Пфайзер Инк. |
Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
|
|
US10106817B2
(en)
|
2013-02-14 |
2018-10-23 |
The J. David Gladstone Institutes |
Compositions and methods of use thereof for identifying anti-viral agents
|
|
IL305629A
(en)
|
2013-02-15 |
2023-11-01 |
Univ California |
Chimeric antigen receptor and methods of using it
|
|
ES2749624T3
(es)
|
2013-03-14 |
2020-03-23 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
|
|
SG11201507393TA
(en)
|
2013-03-14 |
2015-10-29 |
Salk Inst For Biological Studi |
Oncolytic adenovirus compositions
|
|
JP2016524590A
(ja)
|
2013-03-14 |
2016-08-18 |
エペイウス バイオテクノロジーズ コーポレイション |
遺伝子療法適用のためのチミジンキナーゼ診断アッセイ
|
|
JP2016513682A
(ja)
|
2013-03-15 |
2016-05-16 |
ダイアックス コーポレーション |
抗血漿カリクレイン抗体
|
|
CN105189560A
(zh)
|
2013-05-07 |
2015-12-23 |
瑞纳神经科学公司 |
抗胰高血糖素受体抗体和其使用方法
|
|
SMT202000401T1
(it)
|
2013-06-10 |
2020-11-10 |
Ipierian Inc |
Metodi di trattamento di una taupatia
|
|
SG11201510369WA
(en)
|
2013-06-25 |
2016-01-28 |
Univ Canberra |
Methods and compositions for modulating cancer stem cells
|
|
WO2015006641A2
(en)
|
2013-07-12 |
2015-01-15 |
Georgia State University Research Foundation, Inc. |
Methods and compositions for interference with dna polymerase and dna synthesis
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
MX371455B
(es)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
|
|
CA2923765C
(en)
|
2013-09-18 |
2021-06-29 |
University Of Canberra |
Stem cell modulation ii
|
|
CN105814081B
(zh)
|
2013-11-13 |
2021-02-02 |
辉瑞大药厂 |
肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
|
|
EP3760719A1
(de)
|
2013-11-18 |
2021-01-06 |
CRISPR Therapeutics AG |
Crispr-cas-systemmaterialien und verfahren
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
EP3835419A1
(de)
|
2013-12-12 |
2021-06-16 |
The Regents of The University of California |
Verfahren und zusammensetzungen zur modifizierung einer einzelsträngigen zielnukleinsäure
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
MX378344B
(es)
|
2014-03-21 |
2025-03-10 |
Teva Pharmaceuticals Int Gmbh |
Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
|
|
IL247942B
(en)
|
2014-03-27 |
2022-09-01 |
Dyax Corp |
Compositions and methods for drops in macular edema as a result of diabetes
|
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
|
JP6652932B2
(ja)
|
2014-06-18 |
2020-02-26 |
アルバート アインシュタイン カレッジ オブ メディシン |
synTacポリペプチド及びその使用
|
|
WO2015200905A2
(en)
|
2014-06-28 |
2015-12-30 |
Oligasis, Llc |
Dual pdgf/vegf antagonists
|
|
EP3177640B1
(de)
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
Hochaffine pd-1-wirkstoffe und verfahren zur verwendung
|
|
AU2015309686B2
(en)
|
2014-08-25 |
2020-05-14 |
Epiaxis Therapeutics Pty Ltd |
Compositions for modulating cancer stem cells and uses therefor
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
DK3186284T3
(da)
|
2014-08-28 |
2022-05-09 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
WO2016040441A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
ES2899913T3
(es)
|
2014-09-24 |
2022-03-15 |
Salk Inst For Biological Studi |
Virus tumorales oncolíticos y métodos de uso
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
CA2972800A1
(en)
|
2015-01-02 |
2016-07-07 |
Dyax Corp. |
Bispecific antibodies against plasma kallikrein and factor xii
|
|
CA3091771C
(en)
|
2015-03-13 |
2026-04-28 |
The Jackson Laboratory |
A three-component crispr/cas complex system and uses thereof
|
|
EP4212175A1
(de)
|
2015-04-06 |
2023-07-19 |
Bioverativ USA Inc. |
Humanisierte anti-c1s-antikörper und verfahren zur verwendung davon
|
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
|
WO2016164371A1
(en)
|
2015-04-07 |
2016-10-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods for inducing cell division of postmitotic cells
|
|
HUE057285T2
(hu)
|
2015-04-13 |
2022-04-28 |
Pfizer |
Terápiás ellenanyagok és alkalmazásaik
|
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
|
EP3325516B1
(de)
|
2015-07-21 |
2021-12-15 |
Takeda Pharmaceutical Company Limited |
Monoklonaler inhibitorischer antikörper gegen faktor xiia
|
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
|
EP3331536A4
(de)
|
2015-08-03 |
2019-03-27 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
|
|
EP3337827B1
(de)
|
2015-08-19 |
2026-07-08 |
Pfizer Inc. |
Gewebefaktorsignalweginhibitor-antikörper und verwendungen davon
|
|
RU2760582C2
(ru)
|
2015-09-02 |
2021-11-29 |
Иммутеп С.А.С. |
Анти-LAG-3 антитела
|
|
EA038146B1
(ru)
|
2015-09-15 |
2021-07-13 |
Сколар Рок, Инк. |
Антитела к про-/латентному миостатину и их применения
|
|
WO2017064546A1
(en)
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
|
IL258491B2
(en)
|
2015-10-16 |
2023-09-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a particular lineage
|
|
EP3365369A1
(de)
|
2015-10-23 |
2018-08-29 |
Pfizer Inc |
Anti-il-2-antikörper sowie zusammensetzungen und verwendungen davon
|
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
|
IL290457B2
(en)
|
2015-12-30 |
2025-02-01 |
Kodiak Sciences Inc |
Antibodies and their conjugates
|
|
MX2018008416A
(es)
|
2016-01-08 |
2019-11-11 |
Univ California |
Polipéptidos heterodímericos condicionalmente activos y métodos para su uso.
|
|
ES2904593T3
(es)
|
2016-01-21 |
2022-04-05 |
Pfizer |
Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
EP3390645B1
(de)
|
2016-02-23 |
2022-09-14 |
Salk Institute for Biological Studies |
Exogene genexpression eines therapeutischen adenovirus mit geringem einfluss auf die virale kinetik
|
|
WO2017151940A2
(en)
|
2016-03-03 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
WO2020047527A2
(en)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
CN108884460B
(zh)
|
2016-03-19 |
2023-04-28 |
埃克苏马生物技术公司 |
淋巴细胞转导及其扩增调节的方法与组合物
|
|
WO2018161064A1
(en)
|
2017-03-03 |
2018-09-07 |
F1 Oncology, Inc. |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
|
AU2017246794B2
(en)
|
2016-04-04 |
2024-07-04 |
Genzyme Corporation |
Anti-complement factor Bb antibodies and uses thereof
|
|
EP4122958A1
(de)
|
2016-05-13 |
2023-01-25 |
BioAtla, Inc. |
Anti-ror2-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
|
|
IL262606B2
(en)
|
2016-05-18 |
2023-04-01 |
Albert Einstein College Medicine Inc |
pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
|
|
SG11201808552XA
(en)
|
2016-05-18 |
2018-10-30 |
Cue Biopharma Inc |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CA3030003A1
(en)
|
2016-07-08 |
2018-01-11 |
F1 Oncology, Inc. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
AU2017327384B2
(en)
|
2016-09-13 |
2021-05-20 |
The Jackson Laboratory |
Targeted enhanced DNA demethylation
|
|
WO2018057648A1
(en)
|
2016-09-20 |
2018-03-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Peptide regulators of mitochondrial fusion and methods of use
|
|
IL326479A
(en)
|
2016-10-12 |
2026-04-01 |
Bioverativ Usa Inc |
Anti-c1s antibodies and methods of use thereof
|
|
WO2018080573A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
AU2017375633C1
(en)
|
2016-12-12 |
2023-04-27 |
Salk Institute For Biological Studies |
Tumor-targeting synthetic adenoviruses and uses thereof
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
SG10202107808SA
(en)
|
2017-01-18 |
2021-08-30 |
F1 Oncology Inc |
Chimeric antigen receptors against axl or ror2 and methods of use thereof
|
|
EP3571294A1
(de)
|
2017-01-18 |
2019-11-27 |
F1 Oncology, Inc. |
Verfahren zur transduktion und expansion von immunzellen und verwendungen davon
|
|
WO2018148246A1
(en)
|
2017-02-07 |
2018-08-16 |
Massachusetts Institute Of Technology |
Methods and compositions for rna-guided genetic circuits
|
|
WO2018148454A1
(en)
|
2017-02-09 |
2018-08-16 |
The Regents Of The University Of California |
Chimeric t cell antigen receptors and methods of use thereof
|
|
US11198735B2
(en)
|
2017-03-03 |
2021-12-14 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
|
WO2018167621A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
|
CN110678190A
(zh)
|
2017-03-28 |
2020-01-10 |
宾夕法尼亚大学董事会 |
保护移植的组织免受排斥的方法
|
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
|
WO2018200620A1
(en)
|
2017-04-25 |
2018-11-01 |
National Cheng Kung University |
Use of il-20 antagonists for treating eye diseases
|
|
JP7234142B2
(ja)
|
2017-06-02 |
2023-03-07 |
ファイザー・インク |
Flt3に特異的な抗体およびその使用
|
|
CN111033631B
(zh)
|
2017-06-13 |
2024-03-12 |
波士顿基因公司 |
用于生成分子功能谱、对其进行可视化和分类的系统和方法
|
|
CN111065407A
(zh)
|
2017-06-16 |
2020-04-24 |
普罗特利卡公司 |
纤连蛋白结合结构域嵌合抗原受体及其使用方法
|
|
CN110997002A
(zh)
|
2017-07-13 |
2020-04-10 |
麻省理工学院 |
靶向hdac2-sp3复合体以增强突触功能
|
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
|
WO2019051127A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
CN111315773A
(zh)
|
2017-09-08 |
2020-06-19 |
马弗里克治疗公司 |
含有Fc区的条件性活化的结合部分
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
US11970707B2
(en)
|
2017-09-18 |
2024-04-30 |
Children's Hospital Medical Center |
Strong insulator and uses thereof in gene delivery
|
|
AU2018344859A1
(en)
|
2017-10-04 |
2020-04-30 |
Hesperix SA |
Articles and methods directed to personalized therapy of cancer
|
|
CN111527105B
(zh)
|
2017-10-11 |
2024-10-25 |
美国比奥维拉迪维股份有限公司 |
诱导补体活性的方法
|
|
WO2019084343A1
(en)
|
2017-10-25 |
2019-05-02 |
The Administrators Of The Tulane Educational Fund |
PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2019084553A1
(en)
|
2017-10-27 |
2019-05-02 |
New York University |
ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
|
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
|
MX2020008183A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos.
|
|
US11667949B2
(en)
|
2018-02-15 |
2023-06-06 |
The Trustees Of Princeton University |
Reporter construct and biosensor for interferon second messenger 2-5A
|
|
MX387358B
(es)
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
CA3092588A1
(en)
|
2018-03-02 |
2019-09-06 |
Kodiak Sciences Inc. |
Il-6 antibodies and fusion constructs and conjugates thereof
|
|
CN112040986A
(zh)
|
2018-03-15 |
2020-12-04 |
Ksq治疗公司 |
用于改进的免疫疗法的基因调控组合物和方法
|
|
JP7550648B2
(ja)
|
2018-03-19 |
2024-09-13 |
クリスパー セラピューティクス アーゲー |
新規rnaプログラム可能エンドヌクレアーゼ系およびその使用
|
|
US11447769B2
(en)
|
2018-03-27 |
2022-09-20 |
The Trustees Of The University Of Pennsylvania |
Modified immune cells having enhanced function and methods for screening for same
|
|
CA3096202A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
EP3773633A4
(de)
|
2018-04-06 |
2022-01-26 |
The Regents of The University of California |
Verfahren zur behandlung von glioblastomen
|
|
BR112020019942A2
(pt)
|
2018-04-09 |
2021-01-26 |
Salk Institute For Biological Studies |
composições de adenovírus oncolítico com propriedades de replicação aprimoradas
|
|
JP2021524233A
(ja)
|
2018-05-17 |
2021-09-13 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
薬物耐性免疫細胞及びその用途
|
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
|
WO2020010110A1
(en)
|
2018-07-03 |
2020-01-09 |
Unum Therapeutics Inc. |
Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
|
|
WO2020018166A1
(en)
|
2018-07-16 |
2020-01-23 |
The Regents Of The University Of Michigan |
Nuclease-mediated nucleic acid modification
|
|
EP3833444A1
(de)
|
2018-08-09 |
2021-06-16 |
Maverick Therapeutics, Inc. |
Koexpression und reinigungsverfahren von konditionell aktivierten bindungsproteinen
|
|
WO2020037066A1
(en)
|
2018-08-14 |
2020-02-20 |
Unum Therapeutics Inc. |
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
|
|
EP3841205A4
(de)
|
2018-08-22 |
2022-08-17 |
The Regents of The University of California |
Crispr/cas-effektor-polypeptide vom variantentyp v und verfahren zur verwendung davon
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
KR20210102870A
(ko)
|
2018-08-30 |
2021-08-20 |
테나야 테라퓨틱스, 인코포레이티드 |
미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
|
|
CN112805301B
(zh)
|
2018-10-15 |
2023-07-21 |
安立玺荣生医(香港)有限公司 |
粒细胞-巨噬细胞集落刺激因子的抗体及其用途
|
|
WO2020097445A1
(en)
|
2018-11-09 |
2020-05-14 |
Inari Agriculture, Inc. |
Rna-guided nucleases and dna binding proteins
|
|
CA3121191A1
(en)
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體t細胞調節多肽及其使用方法
|
|
TWI851634B
(zh)
|
2018-12-21 |
2024-08-11 |
大陸商沐特圖公司 |
Muc18特異性抗體
|
|
CA3127103A1
(en)
|
2019-01-23 |
2020-07-30 |
New York University |
Antibodies specific to delta 1 chain of t cell receptor
|
|
JP2022524337A
(ja)
|
2019-03-05 |
2022-05-02 |
武田薬品工業株式会社 |
腫瘍抗原を標的とするfc領域及び部分を含有する条件的に活性化された結合タンパク質
|
|
EP4592313A3
(de)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Eingeschränkt bedingt aktivierte bindungsproteine
|
|
WO2020181062A1
(en)
|
2019-03-06 |
2020-09-10 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
JP7691927B2
(ja)
|
2019-03-06 |
2025-06-12 |
キュー バイオファーマ, インコーポレイテッド |
T細胞調節抗原提示ポリペプチド及びその使用方法
|
|
EP4219700A1
(de)
|
2019-03-07 |
2023-08-02 |
The Regents of the University of California |
Crispr-cas-effektorpolypeptide und verfahren zur verwendung davon
|
|
US20220145274A1
(en)
|
2019-03-12 |
2022-05-12 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
|
CN114450411A
(zh)
|
2019-04-01 |
2022-05-06 |
特纳亚治疗股份有限公司 |
具有工程化衣壳的腺相关病毒
|
|
WO2020206033A1
(en)
|
2019-04-02 |
2020-10-08 |
Kenjockety Biotechnology, Inc. |
Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
|
WO2021028726A2
(en)
|
2019-07-03 |
2021-02-18 |
Bostongene Corporation |
Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
|
|
EP3997226A1
(de)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Umprogrammierung von herzzellen mit mikrornas und anderen faktoren
|
|
WO2021020979A1
(en)
|
2019-07-31 |
2021-02-04 |
Memorial Sloan Kettering Cancer Center |
Perfusion modulated tumor dose sculpting with single dose radiotherapy
|
|
US12612657B2
(en)
|
2019-08-16 |
2026-04-28 |
The Jackson Laboratory |
Extrachromosomal DNA labeling
|
|
WO2021062063A1
(en)
|
2019-09-26 |
2021-04-01 |
Chan Zuckerberg Biohub, Inc. |
Improved variants of tev protease for biotechnological applications
|
|
US20240050529A1
(en)
|
2019-10-07 |
2024-02-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
EP4041773A1
(de)
|
2019-10-11 |
2022-08-17 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn-antikörper und verwendungen davon
|
|
FI4034170T3
(fi)
|
2019-10-23 |
2026-04-16 |
Cue Biopharma Inc |
Tgf-beta-polypeptidejä
|
|
WO2021113736A1
(en)
|
2019-12-05 |
2021-06-10 |
Massachusetts Institute Of Technology |
Single-domain antibody to chloramphenicol
|
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
CN115552022A
(zh)
|
2020-03-02 |
2022-12-30 |
特纳亚治疗股份有限公司 |
由心肌细胞表达的微rna控制的基因载体
|
|
US12655229B2
(en)
|
2020-03-18 |
2026-06-16 |
Memorial Sloan Kettering Cancer Center |
Anti-ceramide antibodies
|
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
|
US12686725B2
(en)
|
2020-05-05 |
2026-07-21 |
Mythic Therapeutics, Inc. |
Anti-DLL3 antibodies and methods of use
|
|
US20230181750A1
(en)
|
2020-05-06 |
2023-06-15 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
|
CN116529267A
(zh)
|
2020-06-04 |
2023-08-01 |
肯乔克蒂生物技术股份有限公司 |
Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
|
|
US20230235007A1
(en)
|
2020-06-15 |
2023-07-27 |
Ming-Che Shih |
Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
|
|
JP7797469B2
(ja)
|
2020-07-17 |
2026-01-13 |
ヤンセン バイオテツク,インコーポレーテツド |
抗klk2抗体に対する抗イディオタイプ抗体
|
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
|
WO2022023972A1
(en)
|
2020-07-30 |
2022-02-03 |
Pfizer Inc. |
Cells having gene duplications and uses thereof
|
|
US20230295615A1
(en)
|
2020-08-07 |
2023-09-21 |
The Jackson Laboratory |
Targeted Sequence Insertion Compositions and Methods
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
JP7415042B2
(ja)
|
2020-10-09 |
2024-01-16 |
テナヤ セラピューティクス, インコーポレイテッド |
プラコフィリン2遺伝子治療の方法および組成物
|
|
US20240029829A1
(en)
|
2020-12-04 |
2024-01-25 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
|
WO2022155500A1
(en)
|
2021-01-14 |
2022-07-21 |
Senti Biosciences, Inc. |
Secretable payload regulation
|
|
AU2022229358A1
(en)
|
2021-03-01 |
2023-09-07 |
Exuma Biotech Corp. |
Methods and compositions for the delivery of retroviral particles
|
|
EP4330969A1
(de)
|
2021-04-29 |
2024-03-06 |
BostonGene Corporation |
Maschinenlerntechniken zur schätzung der tumorzellenexpression in komplexem tumorgewebe
|
|
WO2022259190A1
(en)
|
2021-06-10 |
2022-12-15 |
Janssen Biotech, Inc. |
Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof
|
|
MX2023014774A
(es)
|
2021-06-11 |
2024-01-15 |
Bayer Ag |
Nuevos sistemas de endonucleasas programables de arn tipo v.
|
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
|
US20240327496A1
(en)
|
2021-08-02 |
2024-10-03 |
Pfizer Inc. |
Improved Expression Vectors and Uses Thereof
|
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
|
MX2024004009A
(es)
|
2021-09-27 |
2024-06-19 |
Sotio Biotech Inc |
Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos.
|
|
CA3237201A1
(en)
|
2021-11-16 |
2023-05-25 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
|
EP4433512A4
(de)
|
2021-11-19 |
2025-12-31 |
Univ Pennsylvania |
Manipuliertes pan-leukozytenantigen cd45 zur erleichterung der car-t-zelltherapie
|
|
JP2024544054A
(ja)
|
2021-11-30 |
2024-11-27 |
サノフィ パスツール インコーポレイテッド |
ヒトメタニューモウイルスのウイルスベクターに基づくワクチン
|
|
KR20240116829A
(ko)
|
2021-12-13 |
2024-07-30 |
윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 |
항-abcb1 항체
|
|
EP4453191A1
(de)
|
2021-12-23 |
2024-10-30 |
Bayer Aktiengesellschaft |
Neuartige programmierbare endonukleasesysteme für kleine v-rna
|
|
AU2023213817A1
(en)
|
2022-01-31 |
2024-08-01 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
|
EP4473096A1
(de)
|
2022-02-02 |
2024-12-11 |
Pfizer Inc. |
Cysteinprototrophie
|
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
US20250099612A1
(en)
|
2022-03-01 |
2025-03-27 |
Exuma Biotech Corp. |
Viral particles with membrane-bound hyaluronidase
|
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
EP4299739A1
(de)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Zusammensetzungen und verfahren zur genomeditierung
|
|
EP4299733A1
(de)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Zusammensetzungen, systeme und verfahren zum genomeditieren
|
|
US20240029884A1
(en)
|
2022-07-15 |
2024-01-25 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
|
US20260053924A1
(en)
|
2022-08-19 |
2026-02-26 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
|
WO2024044659A1
(en)
|
2022-08-24 |
2024-02-29 |
Tectonic Therapeutic, Inc. |
Constitutively active g protein-coupled receptor compositions and methods of use thereof
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
US20260109972A1
(en)
|
2022-11-09 |
2026-04-23 |
The Regents Of The University Of California |
High-Throughput Discovery of Multi-Partite CRISPR-Based Editors
|
|
WO2024105633A1
(en)
|
2022-11-18 |
2024-05-23 |
Kyoto Prefectural Public University Corporation |
Compositions for mitophagy induction and uses thereof
|
|
US20260209732A1
(en)
|
2022-12-13 |
2026-07-23 |
Bayer Aktiengesellschaft |
Engineered type v rna programmable endonucleases and their uses
|
|
KR20250141243A
(ko)
|
2023-02-06 |
2025-09-26 |
블루록 테라퓨틱스 엘피 |
데그론 융합 단백질 및 그의 생산 및 사용 방법
|
|
WO2024178397A2
(en)
|
2023-02-24 |
2024-08-29 |
Elevatebio Technologies, Inc. |
Modified immune effector cells and methods of use
|
|
CN120957741A
(zh)
|
2023-03-13 |
2025-11-14 |
宾夕法尼亚大学董事会 |
用于肿瘤治疗的car修饰剂的产生
|
|
WO2024189583A1
(en)
|
2023-03-15 |
2024-09-19 |
Kyoto Prefectural Public University Corporation |
Peptide expression constructs and uses thereof
|
|
WO2024215987A1
(en)
|
2023-04-14 |
2024-10-17 |
Sotio Biotech Inc. |
IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
|
|
EP4694916A1
(de)
|
2023-04-14 |
2026-02-18 |
SOTIO Biotech Inc. |
Gentechnisch veränderte immunzellen zur behandlung von krebs in kombination mit il-2/il-15-rezeptor agonisten
|
|
GB202307563D0
(en)
|
2023-05-19 |
2023-07-05 |
Univ King Abdullah Sci & Tech |
Methods and compositions
|
|
AU2024277678A1
(en)
|
2023-05-25 |
2025-11-27 |
Dispatch Biotherapeutics, Inc. |
Synthetic cancer antigens as targets for treating cancers
|
|
CN121712794A
(zh)
|
2023-06-29 |
2026-03-20 |
迪斯派奇生物治疗公司 |
合成细胞因子受体
|
|
WO2025030010A1
(en)
|
2023-08-01 |
2025-02-06 |
Vor Biopharma Inc. |
Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
|
|
AU2024324215A1
(en)
|
2023-08-11 |
2026-02-26 |
Abalytics Oncology, Inc. |
Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
|
|
TW202521691A
(zh)
|
2023-10-06 |
2025-06-01 |
美商藍岩醫療公司 |
經工程化之v型rna可程式核酸內切酶及其用途
|
|
US20260120879A1
(en)
|
2023-10-31 |
2026-04-30 |
Bostongene Corporation |
Machine learning technique for identifying ici responders and non-responders
|
|
WO2025111402A1
(en)
|
2023-11-21 |
2025-05-30 |
Board Of Regents Of The University Of Nebraska |
Anti-amyloid beta antibodies and related compositions and methods thereof
|
|
AU2024406222A1
(en)
|
2023-12-20 |
2026-06-04 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
|
|
US20250253011A1
(en)
|
2024-02-02 |
2025-08-07 |
Seven Bridges Genomics Inc. |
Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025199352A2
(en)
|
2024-03-20 |
2025-09-25 |
Juno Therapeutics, Inc. |
Antibodies specific for solute carrier family 34 member 2 (slc34a2)
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2026006767A1
(en)
|
2024-06-28 |
2026-01-02 |
Dispatch Biotherapeutics, Inc. |
Tethered il-9/il-9r and related engineered cells and methods
|
|
WO2026069312A1
(en)
|
2024-09-24 |
2026-04-02 |
Yeda Research And Development Co. Ltd. |
Immune cells expressing an inducible therapeutic agent and uses thereof
|
|
WO2026117756A2
(en)
|
2024-11-27 |
2026-06-04 |
Dispatch Biotherapeutics, Inc. |
Systems and methods for expression of synthetic cancer antigens and cytokine receptors
|
|
US20260217841A1
(en)
|
2024-12-10 |
2026-07-30 |
Absci Corporation |
Antibodies specific to prolactin receptor and therapeutic uses thereof
|
|
WO2026161387A1
(en)
|
2025-01-21 |
2026-07-30 |
Bristol-Myers Squibb Company |
Cd3 binding molecules and related methods and uses
|
|
WO2026161391A2
(en)
|
2025-01-21 |
2026-07-30 |
Bristol-Myers Squibb Company |
Cd19 binding molecules including cd3- and cd19- bispecific t cell engagers and related methods and uses
|